RWE in Pharma: 5 minutes with…Kraig Kinchen

In this ‘RWE in Pharma’ interview series, we are putting various pharma experts in the spotlight and asking them to share their insight on how their industry has traditionally employed real-world evidence (RWE), how they envision this changing over the next few years, and what their predictions of the impacts of the highly anticipated U.S. FDA RWE Framework may be. This installment features Kraig Kinchen, Senior Director of Value, Evidence and Outcomes at Eli Lilly and Co. (IN, USA). Please could you introduce yourself, your organization(s) and tell us more about your role?  My name is Kraig Kinchen. Approximately half...